journal article·2024-11-26

Multifunctional Microneedle Patches for Perivascular Gene Delivery and Treatment of Vascular Intimal Hyperplasia

Yi Cheng, Xiaoxuan Zhang, Xiangyi Wu, Youjun Ding, Linxi Zhu, Jun Pan, Yuanjin Zhao, Min Zhou

ACS Nano· Volume 18· Issue 47
Publisher page

Abstract

Gene therapy has emerged as a promising approach to address challenging cardiovascular diseases. Extensive efforts have been focused on developing highly efficient gene vectors with precise delivery techniques to enhance its effectiveness. In this study, we present multifunctional dopamine-gelatin microneedle patches with gene therapy capabilities to achieve perivascular gene delivery for intimal hyperplasia treatment. These patches that were fabricated through freeze-drying of gelatin are with recombinant adeno-associated virus (rAAVs)-carrying tips and dopamine coating backing layers. The lyophilized gelatin could not only effectively preserve the therapeutic activity of rAAVs but could also demonstrate the capability to penetrate the adventitia for efficient delivery. The incorporation of dopamine facilitated patch adhesion and extended the release duration. Based on these advantages, we have demonstrated that the rAAVs-loaded microneedle patches (AMNPs) behave satisfactorily in perivascular gene delivery to inhibit carotid artery restenosis in rats. These features indicate that the AMNPs are clinically valuable in the treatment of vascular intimal hyperplasia diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Fluorescence Microscopy Techniques · Microbial Inactivation Methods

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cardiovascular Medical Center, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China

School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China

Funding

National Natural Science Foundation of China

References (49)

Show source-provided references
1. 10.1093/eurheartj/ehae00210.1093/eurheartj/ehae002 ↗
2. 10.1038/s41591-024-02906-x10.1038/s41591-024-02906-x ↗
3. 10.1161/CIRCULATIONAHA.122.06151610.1161/CIRCULATIONAHA.122.061516 ↗
4. 10.1038/s42255-024-01015-w10.1038/s42255-024-01015-w ↗
5. 10.1038/s41569-023-00979-810.1038/s41569-023-00979-8 ↗
6. 10.1056/NEJMra180693910.1056/NEJMra1806939 ↗
7. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
8. 10.1002/SMMD.2022002510.1002/SMMD.20220025 ↗
9. 10.1038/s41467-024-48149-910.1038/s41467-024-48149-9 ↗
10. 10.1038/s41467-023-42740-210.1038/s41467-023-42740-2 ↗
11. 10.1002/adma.20230037410.1002/adma.202300374 ↗
12. 10.1038/s41392-024-01780-w10.1038/s41392-024-01780-w ↗
13. 10.1093/eurheartj/ehac544.309010.1093/eurheartj/ehac544.3090 ↗
14. 10.1161/CIRCULATIONAHA.119.04247610.1161/CIRCULATIONAHA.119.042476 ↗
15. 10.1161/CIRCRESAHA.116.31003910.1161/CIRCRESAHA.116.310039 ↗
16. 10.1016/j.ymthe.2023.10.01510.1016/j.ymthe.2023.10.015 ↗
17. 10.1186/s12951-024-02485-610.1186/s12951-024-02485-6 ↗
18. 10.1038/s41467-022-34898-y10.1038/s41467-022-34898-y ↗
19. 10.1080/14712598.2022.206073710.1080/14712598.2022.2060737 ↗
20. 10.1161/CIRCULATIONAHA.122.06375910.1161/CIRCULATIONAHA.122.063759 ↗
21. 10.1038/s41467-024-46194-y10.1038/s41467-024-46194-y ↗
22. 10.1016/j.jconrel.2017.02.01110.1016/j.jconrel.2017.02.011 ↗
23. 10.1002/adma.20230583410.1002/adma.202305834 ↗
24. 10.1002/adma.20221090310.1002/adma.202210903 ↗
25. 10.1002/adma.20230241010.1002/adma.202302410 ↗
26. 10.1002/adma.20220882010.1002/adma.202208820 ↗
27. 10.1002/adma.20230758510.1002/adma.202307585 ↗
28. 10.1002/advs.20230412410.1002/advs.202304124 ↗
29. 10.1002/SMMD.2024000710.1002/SMMD.20240007 ↗
30. 10.1002/SMMD.2022002310.1002/SMMD.20220023 ↗
31. 10.1016/j.progpolymsci.2023.10174010.1016/j.progpolymsci.2023.101740 ↗
32. 10.1016/j.ijbiomac.2020.07.19510.1016/j.ijbiomac.2020.07.195 ↗
33. 10.1016/j.msec.2021.11254410.1016/j.msec.2021.112544 ↗
34. 10.3390/antiox1209176410.3390/antiox12091764 ↗
35. 10.1016/j.cej.2021.13337210.1016/j.cej.2021.133372 ↗
36. 10.1016/j.ijpharm.2023.12356410.1016/j.ijpharm.2023.123564 ↗
37. 10.1016/j.ijpharm.2021.12091210.1016/j.ijpharm.2021.120912 ↗
38. 10.1016/j.vaccine.2015.08.08510.1016/j.vaccine.2015.08.085 ↗
39. 10.1016/j.scib.2017.09.00610.1016/j.scib.2017.09.006 ↗
40. 10.1126/sciadv.aaz362110.1126/sciadv.aaz3621 ↗
41. 10.1093/eurheartj/ehad02610.1093/eurheartj/ehad026 ↗
42. 10.1001/jamainternmed.2021.003010.1001/jamainternmed.2021.0030 ↗
43. 10.1093/eurheartj/ehae58910.1093/eurheartj/ehae589 ↗
44. 10.1016/j.pmatsci.2022.10092210.1016/j.pmatsci.2022.100922 ↗
45. 10.1007/s40843-016-5151-610.1007/s40843-016-5151-6 ↗
46. 10.1016/j.jconrel.2014.07.00710.1016/j.jconrel.2014.07.007 ↗
47. 10.3390/vaccines1201006510.3390/vaccines12010065 ↗
48. 10.3390/v1606094210.3390/v16060942 ↗
49. 10.1002/SMMD.2022001910.1002/SMMD.20220019 ↗